Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29948 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Marie-Laure Chaix und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de virologie, Hôpital Saint-Louis, APHP, Paris, France. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Antibodies, Neutralizing, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Surveillance studies of Transmitted Drug Resistance (TDR) are crucial in tracking the evolution of HIV epidemiology. Our aim was to investigate TDR to nucleoside reverse transcriptase inhibitors (NRTIs), non‐nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs), as well as to new drugs: lenacapavir, fostemsavir. Predictive sensitivity was evaluated for maraviroc and broadly neutralizing antibodies (bNAbs) (zinlirvimab and teropavimab). Between 2020 and 2023, 85 people with HIV (PWH) were diagnosed with primary HIV‐1 infection (PHI). Pol and env sequences were analyzed and TDR was characterized according to the French ANRS algorithm. The genotypic‐based prediction of bNAbs sensitivity was based on HIV env amino acid signatures I108, I201, F353 for teropavimab and N325, N332, H330 for zinlirvimab. TDR to NRTIs, NNRTIs, PIs and INIs was evidenced in 8.2%, 12.9%, 4.7%, and 5.9% strains, respectively. Ten viruses were CXCR4/dual mix. All viruses were susceptible to lenacapavir (100%) and 52% harbored resistance to fostemsavir. The genotypic profile was associated with a predictive positive value (PPV) > 83% of susceptibility to both teropavimab and zinlirvimab for 23 viruses (31%), while 22 (29%) had a PPV between 62% and 75%, suggesting reduced susceptibility to both bNAbs as soon as primary infection. The surveillance of TDR evidenced at the time of PHI is important with regard to new strategies for HIV patients with virological failure and global implementation of PrEP using NRTI, INI such as recently approved injectable cabotegravir, and future long‐acting drugs such as lenacapavir and bNAbs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire de virologie, Hôpital Saint-Louis, APHP, Paris, France.
- INSERM, U944, Université Paris Cité, Paris, France.
- INSERM, U1259, Université de Tours, Tours, France.
- Laboratoire de Virologie, Centre Hospitalier Régional Universitaire de Tours, Tours, France.
- Department of Maladies Infectieuses, Hôpital Saint-Louis-Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France.
- INSERM, U976 Team INSIGHT, Université Paris Cité, Paris, France.
ORCID-Profile: Karl Stefic, Sarah Maylin, Maud Salmona
Zitieren
APA
Chaix, M. L., Terracol, L., Nere, M. L., Stefic, K., Lascoux-Combe, C., Manda, V., Sellier, P., Maylin, S., Molina, J. M., Liegeon, G., Delaugerre, C., & Salmona, M. (2024). Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023. Journal of Medical Virology. https://doi.org/10.1002/jmv.29948
Vancouver
Chaix ML, Terracol L, Nere ML, Stefic K, Lascoux-Combe C, Manda V, et al. Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023. Journal of Medical Virology. 2024. doi:10.1002/jmv.29948
BibTeX
@article{Chaix2024,
author = {Chaix, Marie-Laure and Terracol, Laura and Nere, Marie-Laure and Stefic, Karl and Lascoux-Combe, Caroline and Manda, Victoria and Sellier, Pierre and Maylin, Sarah and Molina, Jean-Michel and Liegeon, Geoffroy and Delaugerre, Constance and Salmona, Maud},
title = {Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29948}
}
EUVIMED